Pancreatic cancer is highly malignant, with insidious symptoms and not easily detected early, and only about 20% of patients can be treated surgically at diagnosis; however, even after radical surgical resection, the 5-year survival rate is only 20%-25%, and about 10% of patients can live beyond 10 years. Previous studies have found that early staging, negative margins, and absence of lymph node metastases are strongly associated with long-term survival in pancreatic cancer. However, the relationship between individualized genetic mutations and long-term survival in pancreatic cancer patients remains unreported. Researchers from the Johns Hopkins team in the United States studied the genetic profile of patients who survived more than 10 years after pancreatic cancer surgery. They first performed genome-wide exome sequencing to screen for mutation loci of interest in eight patients who survived more than 10 years after surgery, and then validated the mutation profiles of these genes of interest in 27 patients with long-term survival, and found that the mutation frequencies of common genes such as KRAS, TP53, SMAD4 and CDKN2A were not different from those of ordinary pancreatic cancer patients, revealing that pancreatic cancer The common gene mutations were not directly related to long-term survival (>10 years) after pancreatic cancer surgery. Meanwhile, the team compared the clinical and pathological characteristics of these 35 long-term surviving pancreatic cancer patients with 226 common pancreatic cancer patients and found that there were significant differences in age, tumor size, stage, differentiation, cut margins and lymph node status between these 2 groups, with the long-term surviving group showing relatively low age (mean 59 years), smaller primary tumors, earlier stage, high and intermediate differentiation, negative cut margins and no lymph node metastasis. Further study and analysis of these patients with long-term survival beyond 10 years may provide ideas and clues to improve the prognosis of pancreatic cancer. Frequency of common gene mutations in patients with long-term survival (>10 years) after pancreatic cancer surgery